B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy

Oncotarget

Volumn 7, Issue 20, 2016, Pages 29480-29491

  Ma, Juan ^a   Ma, Pan ^b   Zhao, Chenghai ^c   Xue, Xin ^d   Han, Huamin ^e   Liu, Changzhen ^d   Tao, Hua ^e   Xiu, Weigang ^a   Cai, Jia ^a   Zhang, Man ^a,f  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

^d INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^e INSTITUTE OF MICROBIOLOGY   (China)

^f Chinese Medical Doctor Association   (China)

Author keywords

B7 H3; Bispecific antibody; Immunotherapy

Indexed keywords

B7 FAMILY HOMOLOGUE 3 PROTEIN; B7 H3 BISPECIFIC ANTIBODY; BISPECIFIC ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 2; MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; B7 ANTIGEN; CD276 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL THERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; EFFECTOR CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SEVERE COMBINED IMMUNODEFICIENCY; T LYMPHOCYTE ACTIVATION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CYTOTOXICITY; DRUG EFFECTS; DRUG SCREENING; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; PROCEDURES; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; B7 ANTIGENS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MICE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84969895323     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8784     Document Type: Article

References (38)

1. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes. Nature. 2011; 480:480-489.
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-264.
3. Swaika A, Hammond WA, Joseph RW. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol. 2015; 67:4-17.
4. Fousek K, Ahmed N. The evolution of T-cell therapies for solid malignancies. Clinical Cancer Research. 2015; 21:3384-3392.
5. Larkin J, Chiarion-Sileni V, Gonzaler R, Grob JJ, Cowey CL, Lao CD, Schadedof D, Dummer R, Smylie M, Rutkowki P, Ferrucci PF, Hill A, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015; 373:23-34.
6. Lum LG, Thakur A. Targeting T cells with bispecific antibodies for cancer therapy. Bio Drugs. 2011; 25:365-379.
7. Yankelevich M, Kondadasula SV, Thakur A, Buck S, Cheung NV, Lum LG. Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. Pediatr Blood Cancer. 2012; 59:1198-1205.
8. Vaishampayan U, Thakur A, Rathore R, Kouttab N, Lum LG. Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients. Prostate Cancer. 2015; 2015:285193.
9. Lum LG, Thakur A, Al-Kadhimi Z, Colvin GA, Cummings FJ, Legare RD, Dizon DS, Kouttab N, Maizei A, Colaiace W, Liu Q, Rathore R. Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial. Clin Cancer Res. 2015; 21:2305-2314.
10. Loos M, Hedderich DM, Friess H, Kleeff J. B7-H3 and its role in antitumor immunity. ClinDevImmunol. 2010; 2010:683875.
11. Wang L, Kang FB, Shan BE. B7-H3-mediated tumor immunology: Friend or foe? Int J Cancer. 2014; 134:2764-2771.
12. Baral A, Ye HX, Jiang PC, Yao Y, Mao Y. B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients. Oncol Lett. 2014; 8:1195-1201.
13. Brustmann H, Igaz M, Eder C, Brunner A. Epithelial and tumor-associated endothelial expression of B7-H3 in cervical carcinoma: relation with CD8+ intraepithelial lymphocytes, FIGO stage, and phosphohistone H3 (PHH3) reactivity. Int J GynecolPathol. 2015; 34:187-195.
14. Masuda A, Arai K, Nishihara D. Clinical significance of serum soluble T cell regulatory molecules in clear cell renal cell carcinoma. Biomed Res Int. 2014; 2014:396064.
15. Zhang G, Xu Y, Lu X, Huang H, Zhou Y, Lu B, Zhang X. Diagnosis value of serum B7-H3 expression in non-small cell lung cancer. Lung cancer. 2009; 66:245-249.
16. Yamato I, Sho M, Nomi T, Akahori T, Shimada K, Hotta K, Kanehiro H, Konishi N, Yagita H, Nakajima Y. Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer. 2009; 101:1709-1716.
17. Sun TW, Gao Q, Qiu SJ, Zhou J, Wang XY, Yi Y, Shi JY, Xu YF, Shi YH, Song K, Xiao YS, Fan J. B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence. Cancer ImmunolImmunother. 2012; 61:2171-2182.
18. Suh WK, Gajewska BU, Okada H, Gronski MA, Bertram EM, Dawicki W, Duncan GS, Bukzynski J, Plyte S, Elia A, Wakeham A, Itie A, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol. 2003; 4:899-906.
19. Zhang P, Yu SW, Li HY, Liu CY, Li J, Lin WL, Gao A, Wang LL, Gao W, Sun YP. ILT4 drives B7-H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7-H3 co-expression correlates with poor prognosis in non-small cell lung cancer. FEBS Lett. 2015; 589:2248-2256.
20. MaoY, Li W, Chen K, Xie Y, Liu Q, Yao M, Duan W, Zhou X, Liang R, Tao M. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget. 2015; 6:3452-3461. doi: 10.18632/oncotarget.3097.
21. Zhao X, Zhang GB, Gan WJ, Xiong F, Li Z, Zhao H, Zhu DM, Zhang B, Zhang XG, Li DC. Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma. OncolLett. 2013; 5:805-812.
22. Kang FB, Wang L, Jia HC, Li D, Li HJ, Zhang YG, Sun DX. B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-tomesenchymal transition via JAK2/STAT3/Slug signaling pathway. Cancer Cell Int. 2015; 15:45.
23. Xu H, Cheung IY, Guo HF, Cheung NK. MicroRNAmiR-29 modulates expression of immuno-inhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res. 2009; 69:6275-6281.
24. Kramer K, Kushner BH, Modak S, Pandit-Taskar N, Smith-Jones P, Zanzonico P, Humm JL, Xu H, Wolden SL, Souweidane MM, Larson SM, Cheung NK. Compartmental intrathecalradioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol. 2010; 97; 409-418.
25. Seliger B, Quandt D. The expression, function, and clinical relevance of B7 family members in cancer. CancerImmunolImmunother. 2012; 61:1327-1341.
26. Loo D, Alderson R, Chen F, Huang L, Zhang W, Gorlatov S, Burke S, Ciccarone V, Li H, Yang Y, Son T, Chen Y, Easton A, et al. Development of an Fc-Enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res. 2012; 18:3834-3845.
27. Ma J, Han H, Liu D, Li W, Feng H, Xue X, Wu X, Niu G, Zhang G, Zhao Y, Liu CZ, Tao H, Gao B. HER2 as a promising target for cytotoxicity T cells in human melanoma therapy. PLoS ONE. 2013; 8:e73261.
28. Han H, Ma J, Zhang K, li W, Liu C, Xue X, Zhang Y, Zhang G, Ma P, Wang L, Zhang G, Tao H, Gao B. Bispecific anti-CD3×anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo. International journal of oncology. 2014; 45:2446-2454.
29. Lum LG, Davol PA, Lee RJ. The new face of bispecific antibodies: targeting cancer and much more. ExpHematol. 2006; 34:1-6.
30. Renner C, Held G, Ohnesorge S, Bauer S, Gerlach K, Pfitzenmeier JP, Pfreundschun M. Role of perforin, granzymes, and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibodyactivated cytotoxic T cells. Cancer ImmunolImmunother. 1997; 44:70-76.
31. Davol PA, Gall JM, Grabert RC, Lum LG: Infusions of T cells armed with anti-CD3 x anti-her2/neubispecific antibody modulate in vivo patient immune responses in phase I clinical trials for breast and hormone refractory prostate cancers. [abstract]. Blood. 2004; 104:379a.
32. Davol PA, Gall JM, Young WB, Lum LG. Clinical immune responses in breast and hormone refractory prostate patients treated with T cells armed with anti-CD3 x anti-her2/ neubispecific antibody in phase I clinical trials [abstract]. ExpHematol. 2005; 33.
33. Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, Davol PA, Lum LG. Human T cells armed with Her/ neubispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clinical Cancer Research. 2006; 12:569-576.
34. Yano H, Thakur A, Tomaszewski EN, Choi M, Deol A, Lum LG. Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. J Transl Med. 2014; 12:191.
35. Ma P, He Q, Li W, Li X, Han HM, Jin M, Liu CZ, Tao H, Ma J, Gao B. Anti-CD3 x EGFR bispecific antibody redirects cytokine-induced killer cells to glioblastoma in vitro and in vivo. Oncology report. 2015; 34:2567-2575.
36. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers antitumor reactivity. J Immunol. 1999; 163:507-513.
37. Fu X, Tao L, Rivera A, Williamson S, Song XT, Ahmed N, Zhang X. Simple and sensitive method for measuring tumor-specific T cell cytotoxicity. PLoS ONE. 2010; 5:e11867.
38. Brown CE, Wright CL, Naranjo A, Vishwanath RP, Chang WC, Olivares S, Wagner JR, Bruins L, Raubitschek A, Cooper LJ, et al. Biophotonic cytotoxicity assay for highthroughput screening of cytolytic killing. J Immunol Methods. 2005; 297:39-52.